??Electron micrograph showing increased mitochondrial mass after acquisition of anticancer drug resistanceInvolvement of mitochondria in the acquisition mechanism of anticancer drug resistance in pancreatic cancer cellsMultidisciplinary Treatment for Rectal Cancer Chemoradiotherapy → total pelvic exenteration combined sacral resectionAnalysis of resistance signals of KRAS G12C inhibitors (Sotrasiband Adagrasib) and G12D inhibitor (MRTX1133)信州大学医学部医学科発行年月：２０２４年７月発行：信州大学医学部19Hepatobiliary pancreatic surgeryChief：Associate Prof. Akira ShimizuDigestive tract surgeryResearch subjectOutlook for researchForhepato-biliary-pancreaticmalignantdiseasesforwhichthetreatmenteffectisinsufficientwithsurgeryoranti-tumordrugsalone,treatmentresultswillbeimprovedbyprovidinganewtreatmentoptionthatcombinesthesetwo.Thecombinationofmoreefficientadjuvanttherapyandorganfunctionimprovementtherapyenablesaggressivesurgicaltherapyandimprovesthesafetyofsurgery.Outlook for students after graduationDoctorscanbuildcareersasresearchersinourlaboroverseastudyprogram,orasspecialistsinhepatobiliarypancreaticsurgeryinUniversityHospital,orasboardcertifiedsurgeonsingastroenterologyintheaffiliatedhospitals.Chief：Senior Lecture. Research subjectWefocusonpreventingrecurrentlaryngealnerveinjuryduringesophagealcancersurgeryandquantifyingintestinalbloodflowtopreventsutureinsufficiency.Additionally,we'redevelopingtherapiesforKRAS-mutantcolorectal/pancreaticcancerandanalyzingmutatedRhoAingastriccancer.Outlook for researchUsinggeneeditingtechnologieslikeCRISPR-Cas9,alongwithflowcytometryandcellimagingequipment(Operetta),wecanswiftlyassessthefunctionalityanddrugresistanceofvariousgeneticmutations.Ourgoalistoleveragethesefindingstopioneerinnovativetreatmentapproachesforcolorectal,stomach,pancreaticcancers,andbeyond.Outlook for students after graduationBecauseyoucanlearnawiderangeofbasicknowledgeofcancerandresearchmethodusingthelatestequipment,inthecaseofgettinginvolvedincancerresearchandclinicalwork,theknowledgeandtechnologyobtainedinthisstudyseemsveryuseful.SurgerySurgeryMasato KitazawaRegenerative medicine and treatment of malignancy -bench to bedside -From high quality surgery to gene therapy-New challenge to cancer treatment -Surgical resection is the first choice of treatment for malignant hepatobiliary and pancreatic diseases, but there are many issues that need to be addressed. We are conducting research that will contribute to clinical medicine, such as elucidating the mechanism of anticancer drug resistance acquisition by focusing on oxidative phosphorylation by mitochondria in cancer cells, identifying new biomarkers in the fibrosis progression and carcinogenesis processes of MASLD.Elucidation of the mechanism by which pancreatic cancer cells acquire resistance to anticancer drugs and development of drugs that nullify resistanceElucidation of immune responses in the microenvironment and development of therapeutic drugs through cell-to-cell communication analysis using MASLD model mice and single cell RNA sequencingWespecializeintreatingesophageal,gastric,andcolorectalcancers,utilizingrobot-assistedsurgeryforminimallyinvasiveprocedures.Ourapproachincludesmultidisciplinarytreatmentslikepreoperativechemotherapyandchemoradiotherapy.Wealsofocusonbasicresearchtodevelopnoveltreatmentstargetingdrivergenesindigestivecancers,suchasKRASmutationsincolorectalcancerandRhoAgenemutationsindiffuse-typegastriccancer.
元のページ ../index.html#24